Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397954 · ClinicalTrials.gov registry record · Phase 2
A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
A Phase 2 study, sponsored by Ophthotech Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02397954: Completed Phase 2 study, sponsored by Ophthotech Corporation.
NCT02397954 is a Phase 2 study that has completed, run by Ophthotech Corporation. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02397954, a Phase 2 study, has completed, sponsored by Ophthotech Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).
Interventions
- DRUG Avacincaptad Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-03-12 |
| Est. Completion | 2015-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02397954
The ClinicalTrials.gov registry entry for NCT02397954 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthotech Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avacincaptad Pegol is the first listed.
NCT02397954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02397954 about?
NCT02397954 is a clinical study titled "A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)". The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).
What is the current status of trial NCT02397954?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-03-12. Estimated completion is 2015-10-23.
What interventions are being tested in trial NCT02397954?
The interventions under investigation include: Avacincaptad Pegol (DRUG).
Who is sponsoring clinical trial NCT02397954?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.